SCHEMBL17018112

SCHEMBL17018112

COC(=O)N1c2ccc(-c3cnn(CCS(C)(=O)=O)c3)cc2N(C(=O)OC(C)C)C[C@@H]1C

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 14/20 0.55
▸ KDM1A O60341 1/20 0.41
▸ CREBBP Q92793 4/20 0.37
▸ NAMPT P43490 1/20 0.37
▸ LIPC P11150 2/20 0.36
▸ LIPG Q9Y5X9 1/20 0.36
▸ IDH1 O75874 1/20 0.34
▸ PRKAB2 O43741 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ LYN P07948 1/20 0.33
▸ PRKAG1 P54619 1/20 0.33
▸ SIK1 P57059 1/20 0.33
▸ PRKAA1 Q13131 1/20 0.33
▸ SIK2 Q9H0K1 1/20 0.33
▸ SIK3 Q9Y2K2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17018098 0.93 BRD4 (0.65) BRD4KDM1ANAMPT
SCHEMBL17018103 0.91 BRD4 (0.54) BRD4KDM1ANAMPTLIPCLIPG
SCHEMBL17018118 0.91 BRD4 (0.52) BRD4CREBBPNAMPTIDH1PRKAB2
SCHEMBL17018117 0.89 BRD4 (0.51) BRD4NAMPTLIPCLIPGIDH1
SCHEMBL17018261 0.88 BRD4 (0.49) BRD4CREBBPNAMPT
SCHEMBL17018266 0.88 BRD4 (0.49) BRD4NAMPTLIPCLIPGIDH1
SCHEMBL16722066 0.86 BRD4 (0.51) BRD4CREBBPNAMPTIDH1
SCHEMBL17018113 0.86 BRD4 (0.51) BRD4CREBBPNAMPTPRKAB2ABL1
SCHEMBL17018120 0.86 BRD4 (0.51) BRD4CREBBPNAMPT
SCHEMBL17018114 0.85 BRD4 (0.47) BRD4CREBBPLIPCLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084831-B1 Benzopiperazine compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2021-08-10 — — US disclosed
EP-3071205-B1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS INC (US) 2020-02-05 — — EP disclosed
US-10377769-B2 Benzopiperazine compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2019-08-13 — — US disclosed
US-20160257699-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 — — US disclosed
US-20160256458-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 — — US disclosed
US-9422281-B2 Benzopiperazine compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-08-23 — — US disclosed
US-20150232465-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232465-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRPF3, BRD7 BRD4 1/4885KDM1A 103/4885CREBBP 28/4885
US-20160256458-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRPF3, BRD7 BRD4 1/4885KDM1A 103/4885CREBBP 28/4885
US-11084831-B1 Benzopiperazine compositions as BET bromodomain inhibitors BRD4, BRPF3, BRD7 BRD4 1/4885KDM1A 103/4885CREBBP 28/4885
US-10377769-B2 Benzopiperazine compositions as BET bromodomain inhibitors BRD4, BRPF3, BRD7 BRD4 1/4885KDM1A 103/4885CREBBP 28/4885
US-20160257699-A1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRPF3, BRD7 BRD4 1/4885KDM1A 103/4885CREBBP 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback